News
-
-
PRESS RELEASE
ASTA Energy Solutions AG reports strong Q1 2026 results, benefiting from accelerating market dynamics and strong commercial momentum
ASTA Energy Solutions AG reports strong Q1 2026 results, with net sales up 15.3% yoy, adjusted EBITDA increased by 68.6%, and net cash position at EUR 38.6 million. Company re-confirms guidance for 2026 -
-
PRESS RELEASE
MRM Health rewarded a €2.6M VLAIO Research Grant to accelerate the development of novel therapeutics that redefine the treatment of immune-mediated inflammatory diseases
MRM Health rewarded a €2.6M VLAIO Research Grant to accelerate the development of novel therapeutics for immune-mediated inflammatory diseases, supported by cutting-edge microbiome research -
PRESS RELEASE
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Sanofi's venglustat granted priority review by FDA for treating type 3 Gaucher disease. Potential first US therapy for neurological manifestations with target action date on November 25, 2026 -
PRESS RELEASE
Communiqué de presse : Le venglustat de Sanofi a été accepté pour un examen prioritaire aux États-Unis afin de traiter la maladie de Gaucher de type 3
Sanofi's venglustat granted priority review by FDA for type 3 Gaucher disease treatment. Potential first US therapy for neurological manifestations. Action date set for Nov 25, 2026 -
PRESS RELEASE
PURE Swiss Opportunity REF (PSO) – completes May 2026 capital increase with a solid result.
PURE Swiss Opportunity REF (PSO) successfully completes CHF 38.9 million capital increase, issuing 302,025 new units at CHF 128.80 per unit. Funds to be used for property acquisitions and debt-to-equity ratio reduction -
-
-
